Back to Authors

Hecht, Gail

https://orcid.org/0000-0002-6877-8463

A5027111971 | I1304196042

Mayo Clinic

Loyola University Medical Center

Citations 4

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections

Open Forum Infectious Diseases | September 8, 2023 | Volume: 10 | Issue: 9 | Pages: No page available

10.1093/ofid/ofad456 | PMID 37691735

1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S562-S563

10.1093/ofid/ofy210.1606

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection

Clinical Infectious Diseases | March 28, 2018 | Volume: 67 | Issue: 8 | Pages: 1198-1204

10.1093/cid/ciy259 | PMID 29617739

Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection: Results. of the PUNCH CD 2 Trial

Open Forum Infectious Diseases | February 1, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available

10.1093/ofid/ofw172.1044